Manufacturing of recombinant therapeutic proteins in microbial systems

  title={Manufacturing of recombinant therapeutic proteins in microbial systems},
  author={Klaus Graumann and Andreas Premstaller},
  journal={Biotechnology Journal},
Recombinant therapeutic proteins have gained enormous importance for clinical applications. The first recombinant products have been produced in E. coli more than 20 years ago. Although with the advent of antibody‐based therapeutics mammalian expression systems have experienced a major boost, microbial expression systems continue to be widely used in industry. Their intrinsic advantages, such as rapid growth, high yields and ease of manipulation, make them the premier choice for expression of… 

Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements

The current technology used for commercial production of recombinant therapeutics in E. coli is summarized and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics are summarized.

Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement

Recent developments for improving protein production in E. coli, S. cerevisiae, and CHO systems are described and compared to previous knowledge in the field to serve as the framework for future discoveries.

Therapeutic glycoprotein production in mammalian cells.

Environmental and recombinant microorganisms for biopharmaceuticals production

The current application of microbes as production platforms for recombinant proteins and its genetic engineering for the use as biopharmaceuticals is presented.

Production of Recombinant Proteins in Bacteria: The Inclusion Bodies Formation and their Use in Biomedicine

It is revealed that friendlier bacterial cultivation leads to production of non-classical IBs (ncIBs), which are composed of properly folded and biologically active proteins, which can be used either for protein isolation (production) or as active nanoparticles.

Production and Purification of Recombinant Proteins from Escherichia coli

The bioproducts obtained after fermentation and purification processes may fulfill the requirements for the development of various diagnostics, therapeutics, or prophylactic agents against different kinds of diseases.

Industrial Scale Production of Important Therapeutic Proteins Using Bacterial Expression System

This chapter review has discussed the major therapeutic proteins, peptide antibiotics and their industrial scale production, and elaborated the benefits of a bacterial host system for a large-scale production of these recombinant products.

Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli

This review aims to shed light on the strategies to improve the expression, purification, and yield ofFab fragments in Escherichia coli expression systems, as well as current advances in the applications of Fab fragments.

Active Protein Aggregates Produced in Escherichia coli

Since recombinant proteins are widely used in industry and in research, the need for their low-cost production is increasing, and interest in understanding the mechanisms of their formation as well as their properties is increasing.



Recombinant antimicrobial peptides efficiently produced using novel cloning and purification processes

This work has developed cost‐effective methods for recombinant production by expressing fusion proteins comprised of multiple copies of the peptides that are efficacious against antibiotic‐resistant and clinically relevant pathogens.

RETRACTED ARTICLE: Strategies for efficient production of heterologous proteins in Escherichia coli

In recent years, the number of recombinant proteins used for therapeutic applications has increased dramatically, and production of these proteins has a remarkable demand in the market, with major challenges is obtaining the high yield of protein at low cost.

Antibodies and Genetically Engineered Related Molecules: Production and Purification

This review aims to highlight the current trends in the design and construction of genetically engineered antibodies and related molecules, the recombinant systems used for their production, and the development of novel affinity‐based strategies for antibody recovery and purification.

Advances in the production of human therapeutic proteins in yeasts and filamentous fungi

Recent advances in the glycoengineering of yeasts and the expression of therapeutic glycoproteins in humanized yeasts have shown significant promise, and are challenging the current dominance of therapeutic protein production based on mammalian cell culture.

Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.

The status of B. subtilis-based vaccine research, either as protein factories or delivery vectors, and some alternatives for a better use of genetically modified strains are presented.

The humanization of N-glycosylation pathways in yeast

Advances in the glycoengineering of yeast and the expression of therapeutic glycoproteins with humanized N-glycosylation structures have shown significant promise — this review summarizes the most important developments in the field.

Review applications of capillary electrophoresis to the analysis of biotechnology‐derived therapeutic proteins

Applications of mass spectrometry as an ancillary technique, used in conjunction with CE, are covered briefly and the use of antibodies as therapeutic proteins is growing and currently antibodies are the largest class of proteins produced by biotechnology.

Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production

The purpose of this review is to summarize important developments and features of this expression system and to examine from an experimental perspective the genetic engineering, protein chemical and molecular design considerations that have to be taken into account for the successful expression of the target recombinant protein.